CSL889

BIOLOGICAL2 trials

Sponsors

CSL Behring

Conditions

Sickle Cell DiseaseSickle Cell Disease Vaso-occlusive Crisis

Phase 1

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

CompletedNCT04285827

CSL BehringSickle Cell Disease

Start: 2021-05-20End: 2023-07-24Updated: 2023-09-06

Phase 2

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

RecruitingNCT06699849

CSL BehringSickle Cell Disease Vaso-occlusive Crisis

Start: 2025-08-07End: 2027-10-22Target: 70Updated: 2026-08-14

Related Papers

Design of the RHEMEDY Study: A Phase 2/3 Safety, Efficacy and Pharmacokinetics Study of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Journal of sickle cell disease.2025-06-01

Phase 1 Study of the Safety and Pharmacokinetics of CSL889 (Hemopexin) in Adults with SCD

Journal of sickle cell disease.2024-06-014 citations

5610845 A PHASE 1 STUDY OF CSL888 (HEMOPEXIN) IN ADULT PATIENTS WITH SICKLE CELL DISEASE

HemaSphere2023-04-013 citations